Integrated Advisors Network LLC Sells 3,468 Shares of Zoetis Inc. (NYSE:ZTS)

Integrated Advisors Network LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,704 shares of the company's stock after selling 3,468 shares during the quarter. Integrated Advisors Network LLC's holdings in Zoetis were worth $4,514,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Mission Wealth Management LP raised its position in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. raised its holdings in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after acquiring an additional 62 shares during the period. HUB Investment Partners LLC lifted its position in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares during the last quarter. Coppell Advisory Solutions LLC boosted its holdings in shares of Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after acquiring an additional 64 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its position in shares of Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after purchasing an additional 65 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Finally, UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $212.75.

Zoetis Trading Up 0.9%

NYSE ZTS traded up $1.57 during trading hours on Friday, reaching $168.71. The company's stock had a trading volume of 5,467,761 shares, compared to its average volume of 2,534,765. The firm has a fifty day simple moving average of $156.65 and a 200-day simple moving average of $164.63. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock has a market cap of $75.11 billion, a P/E ratio of 30.84, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period in the prior year, the firm earned $1.38 earnings per share. Zoetis's revenue for the quarter was up 1.4% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio is currently 35.91%.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.